Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Novel Heterocycles to Study and Develop Therapeutics for Alzheimer’s Disease

EF 2021-22

Résumé
Alzheimers disease (AD) is a disorder that destroys brain cells, causing thinking abilities and memory to deteriorate over time. As per Alzheimers Society of Canada, a continuously growing population with more than 500,000 Canadians over the age of 65 suffer from impaired mental abilities (dementia) due to AD. Unfortunately, due to the complex mechanism of AD, there are limited medications available, and they only ease the symptoms without curing AD completely. In this regard, a major target for treatments is the build-up (aggregation) of toxic amyloid-beta (Aβ) proteins in the brain, which kills brain cells and leads to dementia. This proposal aims to design, synthesize and evaluate a library of novel class of 3-phenylpyrazino[1,2-a]indol-1(2H)-ones as inhibitors of Aβ-aggregation. First, computational software will be used to design a novel library of molecules based on a core structure, and to understand the interactions of these molecules with Aβ aggregates. New synthetic protocols will then be developed to synthesize the library. Subsequently, Aβ aggregation in the presence of the molecules will be monitored over time using a dye that has unique light properties when bound to Aβ, followed by visualization using a microscope to identify anti-Aβ aggregation compounds. Finally, top compounds from this series will undergo colorimetric measurements in mouse brain cells, which are labeled with a reagent for measuring cell viability. I anticipate that the results of this study will lead to the discovery of a novel class of molecules that can bind and prevent the formation of toxic Aβ aggregates in the brain. These outcomes will have the potential to design and develop novel therapeutics in treating AD. In addition, the proposal will generate new knowledge in the field.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
467007
Name
Lee Yui Sun Marvick
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel Heterocycles to Study and Develop Therapeutics for Alzheimer’s Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
2-A]Indol-1(2h)-Ones; 3-Phenylpyrazino[1; Alzheimer'S Disease; Amyloid-Beta Aggregation; Computational Modeling; Drug Discovery; Electron Microscopy Studies; Fluorescence Kinetics Assay; Neuroprotection Studies; Organic Chemistry; Structure-Based-Design
Abstract
Alzheimers disease (AD) is a disorder that destroys brain cells, causing thinking abilities and memory to deteriorate over time. As per Alzheimers Society of Canada, a continuously growing population with more than 500,000 Canadians over the age of 65 suffer from impaired mental abilities (dementia) due to AD. Unfortunately, due to the complex mechanism of AD, there are limited medications available, and they only ease the symptoms without curing AD completely. In this regard, a major target for treatments is the build-up (aggregation) of toxic amyloid-beta (Aβ) proteins in the brain, which kills brain cells and leads to dementia. This proposal aims to design, synthesize and evaluate a library of novel class of 3-phenylpyrazino[1,2-a]indol-1(2H)-ones as inhibitors of Aβ-aggregation. First, computational software will be used to design a novel library of molecules based on a core structure, and to understand the interactions of these molecules with Aβ aggregates. New synthetic protocols will then be developed to synthesize the library. Subsequently, Aβ aggregation in the presence of the molecules will be monitored over time using a dye that has unique light properties when bound to Aβ, followed by visualization using a microscope to identify anti-Aβ aggregation compounds. Finally, top compounds from this series will undergo colorimetric measurements in mouse brain cells, which are labeled with a reagent for measuring cell viability. I anticipate that the results of this study will lead to the discovery of a novel class of molecules that can bind and prevent the formation of toxic Aβ aggregates in the brain. These outcomes will have the potential to design and develop novel therapeutics in treating AD. In addition, the proposal will generate new knowledge in the field.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lee, Yui Sun Marvick
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~